Game-changing potential for Abrysvo and Beyfortus in pediatric RSV sector
US pharma giant Pfizer’s (NYSE: PFE) respiratory syncytial virus (RSV) vaccine Abrysvo (RSVpreF) earlier this month received US Food and Drug Administration (FDA) authorization for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32-36 weeks gestation.
Also, a few weeks ago, UK major AstraZeneca (LSE: AZN) and French partner Sanofi’s (Euronext: SAN) monoclonal antibody (MAb) Beyfortus (nirsevimab) were granted FDA approval for the prevention of RSV LRTD in babies and toddlers. These therapies have the potential to considerably reduce the burden of RSV infection among young children ahead of the 2023/2024 season, says data and analytics company GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze